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Efficacy of broflanilide 
(VECTRON T500), a new 
meta‑diamide insecticide, 
for indoor residual spraying 
against pyrethroid‑resistant 
malaria vectors
Corine Ngufor1,2,3*, Renaud Govoetchan1,2,3, Augustin Fongnikin2,3, Estelle Vigninou2, 
Thomas Syme1,2,3, Martin Akogbeto2 & Mark Rowland1,3 
The rotational use of insecticides with different modes of action for indoor residual spraying (IRS) is 
recommended for improving malaria vector control and managing insecticide resistance. Insecticides 
with new chemistries are urgently needed. Broflanilide is a newly discovered insecticide under 
consideration. We investigated the efficacy of a wettable powder (WP) formulation of broflanilide 
(VECTRON T500) for IRS on mud and cement wall substrates in laboratory and experimental hut 
studies against pyrethroid‑resistant malaria vectors in Benin, in comparison with pirimiphos‑methyl 
CS (Actellic 300CS). There was no evidence of cross‑resistance to pyrethroids and broflanilide in CDC 
bottle bioassays. In laboratory cone bioassays, broflanilide WP‑treated substrates killed > 80% of 
susceptible and pyrethroid‑resistant An. gambiae sl for 6–14 months. At application rates of 100 mg/
m2 and 150 mg/m2, mortality of wild pyrethroid‑resistant An. gambiae sl entering experimental huts 
in Covè, Benin treated with VECTRON T500 was similar to pirimiphos‑methyl CS (57–66% vs. 56%, 
P > 0.05). Throughout the 6‑month hut trial, monthly wall cone bioassay mortality on VECTRON T500 
treated hut walls remained > 80%. IRS with broflanilide shows potential to significantly improve the 
control of malaria transmitted by pyrethroid‑resistant mosquito vectors and could thus be a crucial 
addition to the current portfolio of IRS insecticides.
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Background
Indoor residual spraying (IRS) has historically been shown to be a powerful malaria control  intervention1. 
When applied correctly, IRS can quickly reduce malaria transmission by reducing adult mosquito vector density 
and longevity. It involves the application of a residual insecticide formulation to potential resting surfaces for 
malaria vectors such as internal walls, eaves, and ceilings of houses, giving opportunity for vector mosquitoes to 
contact the insecticide and be killed in the process. IRS contributed substantially to the success of the malaria 
eradication campaign of the 1950s and 60s which resulted in the elimination of malaria from Europe and several 
countries in Asia and the  Caribbean2. The recent reductions in malaria morbidity and mortality observed in 
endemic countries in Africa and Asia over the last two decades has also been partly attributed to a significant 
increase in coverage with  IRS3–5.
The efficacy of IRS for malaria control is unfortunately threatened by widespread resistance in malaria vec-
tors to the rather limited collection of insecticides approved for public health  use6. Pyrethroid resistance is now 
established across Africa and is increasing substantially in intensity the more they are used, making this previ-
ously ideal class of vector control insecticides almost unusable for IRS. Resistance to carbamates and organophos-
phates, which were for many years the only alternative IRS insecticide classes to  pyrethroids5,7 is also increasing 
rapidly in malaria vector populations in  Africa6,8–11. To mitigate the impact of insecticide resistance on malaria 
control, vector control programmes are encouraged to implement a rotational application of insecticides for IRS, 
alternating between insecticides with different modes of  action12. The use of rotations for insecticide resistance 
management relies on the concept that removing selection pressure for a given insecticide by switching between 
different modes of action, will result in resistance declining over time. An IRS rotation plan which will effectively 
reduce selection pressure for existing insecticide resistance genes and prevent the development of further resist-
ance will, however, require a more diversified portfolio of IRS insecticides with more novel modes of action than 
what is currently  available13. This is driving the development of a new generation of IRS insecticide formulations 
containing new chemistries which can provide improved and prolonged control of insecticide-resistant malaria 
vector  populations14–16.
Broflanilide is a novel insecticide discovered by Mitsui Chemicals Agro,  Inc17 which has been formulated 
as a wettable powder for IRS. It has a unique chemical structure characterized as a meta-diamide which acts as 
a non-competitive antagonist (NCA) of the γ-aminobutyric acid (GABA) receptor of chloride channels of the 
insect inhibitory nervous  system18. Broflanilide was classified by the Insecticide Resistance Action Committee 
(IRAC) as a GABA-gated chloride channel allosteric modulator (IRAC Group 30), causing hyperexcitation 
and convulsion in  insects19. Its mode of action is distinct from that of other NCAs of the GABA-gated chloride 
channel, such as picrotoxinin, dieldrin, fipronil, lindane and α-endosulfan20. There is no known cross-resistance 
between broflanilide and current public health insecticides. The active metabolite exhibits high selectivity for the 
insect RDL GABA receptor compared to the mammalian  receptors18 but exhibits no cross-resistance to dieldrin. 
Broflanilide has demonstrated excellent insecticidal activity against many insect species including Lepidopteran 
and Coleopteran pests and Thysanopteran  pests17 and has also shown low acute toxicity against non-target aquatic 
 organisms21, demonstrating high potential for public health and agricultural use.
In this study, we investigated the potential of VECTRON T500, a wettable powder (WP) formulation of bro-
flanilide (broflanilide WP), for indoor residual spraying against mosquito vectors of malaria. The insecticide was 
assessed for its efficacy and residual activity on local IRS wall substrates in a series of WHO phase I laboratory 
bioassays with susceptible Anopheles gambiae s.s. and resistant strains of An. gambiae sl and in WHO phase II 
experimental hut studies against wild free-flying pyrethroid-resistant An. gambiae sl in southern Benin, West 
Africa.
Results
WHO phase I laboratory bioassays. Following WHO  guidelines22, laboratory bioassays were performed 
to investigate possible cross-resistance to broflanilide and pyrethroid-resistance mechanisms in CDC bottle bio-
assays using technical grade insecticide and to identify an effective dose of broflanilide WP (VECTRON T500), 
for IRS using WHO cone bioassays. Cone bioassays were also performed to investigate the residual efficacy of 
broflanilide WP on cement and mud block substrates. The bioassays were conducted using laboratory-main-
tained mosquitoes of the susceptible An. gambiae ss Kisumu strain and the pyrethroid-resistant An. gambiae sl 
Covè strain. The An. gambiae sl Covè strain is susceptible to carbamates and organophosphates but has shown 
over 200-fold resistance to pyrethroids mediated by a high frequency of the knockdown resistance L1014F allele 
(> 90%) and overexpression of the cytochrome P450 CYP6P3, associated with pyrethroid  detoxification23.
No evidence of cross‑resistant to broflanilide and pyrethroids in CDC bottle bioassays. Mosquito mortality fol-
lowing exposure in CDC bottles coated with alpha-cypermethrin 12.5 µg was 100% with the insecticide sus-
ceptible An. gambiae sensu stricto Kisumu strain and 45% with the pyrethroid-resistant An. gambiae sl Covè 
strain thus confirming the high levels of pyrethroid resistance in the Covè  strain23. The mortality results of both 
strains exposed to broflanilide in CDC bottles treated with a range of doses between 5 µg and 200 µg per bot-
tle are presented in Fig. 1 with more details in supplementary information (Table S1). Using log dosage-probit 
mortality analysis, the lethal concentration (LC) required to kill 50% (LC50) and 95% (LC95) of exposed mos-
quitoes were 8.5 µg and 70 µg respectively with the susceptible Kisumu strain and 18.1 µg and 73.6 µg with the 
pyrethroid-resistant Covè strain (Table 1). A small resistance ratio of 2.1 (95% limits: 1.7–2.7) for the Covè strain 
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Dose–response cone bioassay studies. According to WHO  guidelines22, the target dose of a new insecticide for 
IRS should be investigated from doses 2–4 times the minimum dose that will cause 100% mortality in a fully 
susceptible mosquito vector population. To identify a suitable target dose of broflanilide WP for IRS, WHO 
cone bioassays were conducted on cement and mud block substrates treated with a range of concentrations of 
broflanilide WP between 5 and 100 mg/m2, to detect the minimum dose that will cause 100% mortality. The cone 
bioassays were performed 1-week post block treatment using the insecticide-susceptible An. gambiae ss Kisumu 
strain. The mortality rates observed are presented in Fig. 2. No knockdown was recorded with broflanilide WP 
at any of the doses and with any of the substrates tested. Mortality reached 100% within 24 h at a dose of 100 mg/
m2 on cement block substrates (Fig. 2a) and a dose of 12.5 mg/m2 on mud block substrates (Fig. 2b). Broflanilide 
WP performed better on mud than on cement. Data with cement blocks showed a delayed mortality effect with 
broflanilide WP doses below 100 mg/m2 with mortality increasing gradually from 24 h and reaching a peak at 
72 h. At the doses tested, there was no measurable increase in mortality when holding time was extended beyond 
72 h. This demonstrated a delayed mortality effect with broflanilide WP, as a result, for subsequent studies with 
the insecticide, mosquito mortality was recorded only up to 72 h post-exposure.
A dose of 200 mg/m2, which was two times the dose that induced 100% mosquito mortality within 24 h 
on both substrates, was identified as a suitable dose for further laboratory studies on the residual efficacy of 
Figure 1.  Mortality of susceptible An. gambiae Kisumu (red) and pyrethroid-resistant An. gambiae sl Covè 
(blue) mosquitoes in CDC bottle bioassays treated with a technical grade of broflanilide insecticide. Mosquitoes 
(150/dose) were exposed for 1-h in cohorts of 25 per bottle. Based on preliminary findings of delayed mortality 
effect with broflanilide, mortality in bottle bioassays was recorded after 72 h. The red line represents the 
response of the susceptible Kisumu strain while the blue line represents the response of the pyrethroid-resistant 
Covè strain. PoloPlus 1.0, LeOra Software.
Table 1.  Lethal dose of broflanilide on pyrethroid-resistant An. gambiae sl Covè exposed in CDC bottle 
bioassays. a Lethal doses are expressed in µg/ml.
Mosquito strain Slope (SE)
LD50a LD95a Resistance ratio
(95% CI) (95% CI) (95% CI)
Susceptible An. gambiae ss Kisumu 2.7 (0.14) 8.5 (2.2–14.1) 70 (38.5–141.1) –
Pyrethroid-resistant An. gambiae sl Covè 1.8 (0.20) 18.1 (10.7–25.4) 73.6 (46.9–214.9) 2.1 [1.7–2.7]
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broflanilide WP. Since the insecticide performed better on mud block substrates inducing optimal mortality at 
even much lower doses, residual efficacy on mud block substrates was also assessed at 100 mg/m2.
Broflanilide WP shows prolonged residual efficacy on block substrates in laboratory cone bioassays. The residual 
efficacy of broflanilide WP was investigated at application rates of 200 mg/m2 on cement block substrates and 
100 mg/m2 and 200 mg/m2 on mud block substrates. Blocks of each substrate-type were treated at each selected 
dose and tested in WHO cone bioassays at 1-week post-treatment and monthly intervals subsequently using the 
insecticide-susceptible An. gambiae ss Kisumu and the pyrethroid-resistant An. gambiae sl from Covè.
Monthly cone bioassay mortality (72 h) on cement blocks treated at 200 mg/m2 was > 80% with the susceptible 
An. gambiae ss Kisumu strain for 6 months after which it ranged between 57 and 100% up to month 18 post-
treatment (Fig. 3). With the pyrethroid-resistant An. gambiae sl Covè strain, mortality on cement blocks (200 mg/
m2) remained > 80% for up to 14 months post-treatment (Fig. 3). Monthly cone bioassay mortality of both strains 
at both doses tested on mud blocks (100 mg/m2 and 200 mg/m2) remained > 80% for 16 months (Fig. 4).
WHO phase II experimental hut evaluation of broflanilide WP in Covè, Benin. To investigate the 
efficacy of the broflanilide WP formulation for IRS against wild free-flying pyrethroid-resistant malaria vectors, 
we performed an experimental hut trial at the CREC/LSHTM experimental hut station in Covè, southern Benin 
(7°14′N 2°18′E). The local vector population in Covè is resistant to pyrethroids and DDT. Molecular analysis 
has revealed a kdr (L1014F) allele frequency of 89% and microarray studies have also found overexpression of 
CYP6P3, a P450 that is as an efficient metabolizer of  pyrethroids23.
Experimental huts simulate household conditions and are thus used to assess the capacity of indoor vector 
control interventions to prevent mosquito entry, induce early exiting of vector mosquitoes, prevent mosquito 
feeding and induce mosquito mortality under carefully controlled household  conditions22,24. Broflanilide WP 
was evaluated for IRS against wild pyrethroid-resistant An. gambiae sl in Covè in experimental huts treated at 
application rates of 100 mg/m2 and 150 mg/m2. To investigate efficacy on commonly used wall substrates in 
Benin, for each application rate, the inner walls and ceiling of the experimental huts were plastered with either 
cement or mud. Broflanilide WP was compared to the main IRS insecticide used in Benin at the time of the trial, 
pirimiphos-methyl CS (Actellic 300CS) applied at 1000 mg/m2 on cement walls, as a positive control. At the time 
of this study, the toxicity and potential risk of broflanilide WP for IRS was yet to be fully assessed, so it was not 
acceptable to use human volunteer sleepers as hosts to attract wild vector mosquitoes into the experimental huts 
until a human risk-assessment was performed and the product was found safe for IRS at the potential application 
rates. Preliminary studies revealed that the local wild An. gambiae sl at the Covè experimental hut station were 
also attracted to and blood-fed on cows, although less than to humans. Hence, cows were used as replacement 
hosts to attract mosquitoes into the experimental huts during the trial.
Mosquito exiting rates in experimental huts. A total of 745 female An. gambiae sl and 771 female An. ziemanni 
were collected in the experimental huts over the 6-month trial (Tables 2 and 3). Molecular species analysis (SINE 
PCR) performed using the protocol proposed by Santolamazza et al.25 on DNA extracted from a random selec-
Figure 2.  Mortality of insecticide-susceptible An. gambiae ss Kisumu strain mosquitoes on broflanilide WP 
treated cement (a) and mud (b) blocks substrates. Mosquitoes were exposed 1-week post-treatment for 30-min 
in WHO cone bioassays and mortality recorded every 24 h for up to 120 h.
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tion of 100 live and dead An. gambiae sl collected in the experimental huts during the 6-month trial, revealed 
that the vector was composed of 81% An. coluzzii and 19% An. gambiae ss.
Exiting rates of An. gambiae sl were generally higher in broflanilide WP-treated huts (88–92%) compared 
to the control hut (69%; P < 0.05), but not significantly lower than in pirimiphos-methyl CS-treated huts (95%). 
Exiting rates with broflanilide WP did not also differ substantially between the two application rates tested and 
between the two substrates assessed (P > 0.05; Table 2).
Figure 3.  Monthly cone bioassays mortality of insecticide-susceptible An. gambiae ss Kisumu and pyrethroid-
resistant An. gambiae sl Covè strain mosquitoes on broflanilide WP-treated cement block substrates in the 
laboratory. At each time point, forty 2–5 days old female mosquitoes were exposed for 30-min in WHO cone 
bioassays and mortality recorded after 72 h.
Figure 4.  Monthly cone bioassays mortality of insecticide-susceptible An. gambiae ss Kisumu and pyrethroid-
resistant An. gambiae sl Covè strain mosquitoes on broflanilide WP-treated mud block substrates. At each 
monthly time point, forty 2–5 days old female mosquitoes were exposed for 30-min in WHO cone bioassays 
and mortality recorded after 72 h.
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7976  | https://doi.org/10.1038/s41598-021-86935-3
www.nature.com/scientificreports/
A similar trend in mosquito exiting was observed with the An. ziemanni collected in the experimental huts 
except that exiting rates with broflanilide WP-treated huts did not differ significantly from that in the negative 
control hut (P < 0.05) (Table 2).
Broflanilide WP induces similar overall mortality of wild pyrethroid‑resistant An. gambiae s.l. compared to pirimi‑
phos‑methyl CS in experimental huts. Mortality (at 72 h) of free-flying wild, pyrethroid-resistant An. gambiae 
sl entering the control untreated hut was 1% while mortality with broflanilide WP treated huts ranged between 
57 and 66% (Table 2). The mortality rates observed with broflanilide WP were similar to mortality observed 
with pirimiphos-methyl CS (57–66% with broflanilide WP vs. 56% with pirimiphos-methyl CS; P > 0.05). For 
each substrate type, mortality with broflanilide WP did not differ significantly between the doses tested; cement: 
57% with 100 mg/m2 vs 66% with 150 mg/m2 (P = 0.439) and mud: 63% with both application rates (P = 0.922). 
Broflanilide WP generally performed the same on mud and cement substrates at both application rates; at 
100 mg/m2: 57% on cement vs. 63% on mud (P = 0.938) and at 150 mg/m2: 66% with cement vs. 63% with mud 
(P = 0.664). In addition, for each application rate, the difference in mortality between substrates was not signifi-
cant (P > 0.05). As in the phase 1 cone bioassays, the free-flying mosquito experimental hut data also showed 
a delayed mortality effect with broflanilide WP on An. gambiae sl (Fig. 5). Mortality increased steadily from 
35–41% at 24 h to 57–63% at 72 h with the 100 mg/m2 application rate and from 48–52% at 24 h to 63–66% at 
72 h with the 150 mg/m2 application rate (P < 0.05).
Mortality rates achieved with broflanilide WP against An. ziemanni (Table 3) were generally higher than what 
was observed with An. gambiae sl (74–88% vs. 50–61%). Mortality in cement huts did not differ between the 
two application rates tested (74% with 100 mg/m2 vs 77% with 150 mg/m2 (P > 0.05) but for mud-walled huts, 
Table 2.  Results with wild, free-flying pyrethroid-resistant An. gambiae sl entering experimental huts in Covè, 
Benin. Values bearing the same letter superscript along a row are not significantly different at the 5% level 
(P > 0.05, logistic regression).
Insecticide treatment Untreated control Broflanilide WP Pirimiphos-methyl CS
Substrate Cement Cement Mud Cement
Target dose – 100 mg/m2 150 mg/m2 100 mg/m2 150 mg/m2 1000 mg/m2
Total collected 156 107 56 70 88 268
Total exiting 107 95 49 64 70 254
% Exiting 69a 89bd 88bd 91 cd 80ab 95c
95% CI [61–75] [83–95] [79–96] [85–98] [71–88] [92–97]
No. dead after 72 h 2 61 37 44 55 151
% dead after 72 h 1a 57b 66b 63b 63b 56b
95% CI [0–3] [47–66] [54–78] [52–74] [52–72] [50–62]
No blood-fed 154 99 52 66 81 259
% Blood-fed 99a 93b 93ab 94ab 92b 97ab
95% CI [97–100] [88–98] [86–99] [89–100] [87–98] [95–99]
Blood-feeding inhibition (%) – 6 6 5 7 2
Table 3.  Results with wild, free-flying pyrethroid-resistant An. ziemanni entering experimental huts in Covè, 
Benin. Values bearing the same letter superscript along a row are not significantly different at the 5% level 
(P > 0.05).
Treatment Untreated control Broflanilide WP Pirimiphos-methyl CS
Substrate Cement Cement Mud Cement
Target dose – 100 mg/m2 150 mg/m2 100 mg/m2 150 mg/m2 1000 mg/m2
Total collected 92 181 123 67 132 166
Total exiting 79 170 107 64 101 152
% Exiting 86ab 94ac 87ac 96c 77b 92ac
95% CI [79–93] [91–97] [81–92] [91–100] [70–84] [88–96]
No. dead after 72 h 4 136 95 49 115 128
% dead after 72 h 4a 75b 77bc 73b 87c 77b
95% CI [0–8] [67–81] [70–85] [62–83] [82–93] [70–83]
No. blood-fed 92 171 112 67 112 162
Blood-feeding % 100a 94a 91a 100a 85b 98 a
95% CI [95–100] [91–98] [86–96] [95–100] [79–91] [95–100]
Blood-feeding inhibition (%) – 6 9 – 15 2
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mortality was significantly higher with the higher application rate of broflanilide WP (P < 0.05). Mortality rates 
achieved with broflanilide WP on cement walls were also similar to what was observed with pirimiphos-methyl 
CS (P > 0.05). Broflanilide WP also induced delayed mortality with An. ziemanni entering huts during the trial.
Blood‑feeding rates of wild pyrethroid‑resistant An. gambiae sl in experimental huts. As expected of IRS treat-
ments, blood-feeding rates of both mosquito species were generally very high across all huts (> 90%). For pyre-
throid-resistant An. gambiae sl, there was no significant difference in blood-feeding rates between the two appli-
cation rates (100 mg/m2 and 150 mg/m2) of broflanilide WP for either substrate type (P > 0.05, Table 2). With 
An. ziemanni, while a significantly lower blood-feeding rate was observed with the higher dose of broflanilide 
WP in mud-walled huts, all other treatments tested gave similar blood-feeding rates irrespective of substrate 
type (Table 3).
Mosquito mortality in cone bioassays on experimental hut walls treated with broflanilide WP is high and prolonged, 
lasting over 6 months. To assess the residual efficacy on the different hut wall substrates (mud and cement), 
monthly 30-min cone bioassays were performed using unfed pyrethroid-resistant An. gambiae sl Covè and 
insecticide-susceptible An. gambiae ss Kisumu strains. The results from the wall cone bioassays are presented in 
Figs. 6 and 7. Broflanilide WP performed better on cement and mud wall substrates compared to pirimiphos-
methyl CS. For both strains, cone bioassay mortality with broflanilide WP remained over 80% with both doses 
and substrates throughout the 6-month trial while a drop below 80% was observed with pirimiphos-methyl CS 
within 2–4 months.
Assessment of IRS application quality. To assess the quality of the IRS applications in the experimental huts, 
prior to spraying, filter papers measuring 5 cm × 5 cm were fixed on the hut walls to be sprayed as described 
in the WHO  guidelines22. After spraying, they were left to dry for 1 h and then wrapped in aluminium foil and 
stored at 4° C (± 2 °C) after which they were shipped within 2 weeks after IRS application to the Liverpool School 
of Tropical Medicine for chemical analysis by HPLC. The summary results showed that the IRS treatment appli-
cations rates were generally within an acceptable deviation of < 50% from the target dose as recommended by 
 WHO26 (Table 4).
Discussion
There is a critical need for new insecticides with novel modes of action for indoor residual spraying against 
malaria vectors. We investigated the bioefficacy of a newly discovered insecticide,  broflanilide17, as an indoor 
residual treatment in WHO phase I laboratory bioassays and phase II experimental hut  studies22. Broflanilide 
binds to the γ-aminobutyric acid (GABA) receptor of the chloride channel at a different site to the cyclodiene 
insecticide dieldrin and the phenyl pyrazole fipronil and thus presents a new mode of action for malaria vector 
control.
VECTRON T500, a wettable powder formulation of broflanilide was assessed for IRS against pyrethroid-
susceptible and pyrethroid-resistant strains of An. gambiae sl on the principal wall substrates used in village-type 
Figure 5.  Overall mortality of wild free-flying pyrethroid-resistant An. gambiae sl at 24, 48 and 72 h after 
collection from experimental huts in Covè, Benin. Bars bearing the same letter label are not significantly 
different at the 5% level (logistic regression). Error bars represent 95% confidence intervals. Broflanilide WP 
induced a delayed mortality effect on wild vector mosquitoes in experimental huts.
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housing in Benin. The results clearly demonstrate the potency of the insecticide, inducing high vector mosquito 
mortality at doses as low as 5 mg/m2 in laboratory cone bioassays. In experimental hut studies, VECTRON T500, 
when used for IRS in housing in southern Benin at application rates of 100 mg/m2 and 150 mg/m2, showed 
similar performance to Actellic 300CS, a WHO approved IRS insecticide, killing substantial proportions of wild 
free-flying pyrethroid-resistant malaria vector mosquitoes which entered the hut (57–66%), for 6-months. At 
Figure 6.  Cone bioassays mortality (72 h) with susceptible An. gambiae ss Kisumu on broflanilide WP treated 
experimental hut walls. At each monthly interval, ~ 50 2–5 days old female mosquitoes were exposed on 
treated walls of each hut in cohorts of 10 per cone. Error bars represent 95% confidence intervals.
Figure 7.  Cone bioassays mortality (72 h) with pyrethroid-resistant An. gambiae sl Covè on Broflanilide 
WP-treated experimental hut walls. At each monthly interval, ~ 50 2–5 days old female mosquitoes were 
exposed on treated walls of each hut in cohorts of 10 per cone. Error bars represent 95% confidence intervals.
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both levels of evaluation, mosquito mortality with VECTRON T500 was high but slow acting compared to what 
is achievable with most neurotoxic public health insecticides, lasting up to 72 h post-exposure. This delayed 
activity could be attributed to its mechanism of action; broflanilide has to be metabolized to its active form, 
desmethyl-broflanilide, before binding to its site of  action18. Delayed mosquito mortality effects has also been 
observed with  clothianidin14,27 and  chlorfenapyr15,28 which are the main active ingredients in newly approved 
IRS insecticide formulations and insecticide treated nets for malaria vector  control13. While the relative impact 
of such slow acting insecticides is yet to be fully assessed, modelling studies have suggested that development of 
resistance to these insecticides may be slower compared to fast-acting neurotoxic  insecticides29.
One of the main objectives of this study was to identify a suitable IRS application rate of VECTRON T500 for 
field use. The hut trial results showed no difference in wild vector mosquito mortality between the two applica-
tion rates tested, hence the lower dose of 100 mg/m2 was chosen for operational use of the insecticide in com-
munities. Recent human risk assessment studies have also shown acceptable tolerance of broflanilide for IRS at 
this application rate. Further studies to assess the efficacy of VECTRON T500 applied at 100 mg/m2 in human 
occupied experimental housing and in village communities are underway in Benin and Tanzania.
Longer lasting IRS insecticide formulations are ideal for most endemic areas in Africa characterised by stable 
and extended malaria transmission as they offer continuous protection without the need for multiple resource-
demanding and labour-intensive IRS campaigns. Earlier experimental hut studies in Benin which demonstrated 
for the first time the potential of the micro-encapsulated formulation of pirimiphos-methyl (Actellic 300CS) to 
provide improved and prolonged control of pyrethroid-resistant vector populations lasting 6–9 months when 
applied on cement  walls30, were followed by several reports of significantly improved malaria control with one 
annual IRS campaign with this insecticide in many epidemiological settings across  Africa31–33. In laboratory 
cone bioassays, mortality of susceptible and pyrethroid-resistant vector mosquito strains with VECTRON T500 
remained > 80% for 6–14 months on mud and cement block substrates. Likewise, throughout the 6-month 
experimental hut trial, vector mosquito mortality in in situ wall cone bioassays in huts treated with VECTRON 
T500, remained > 80% demonstrating the potential of the insecticide to provide prolonged vector control and 
significantly improved malaria control in many endemic areas in Africa. While the residual efficacy of the insec-
ticide was assessed in the hut trial for only 6 months, the laboratory cone bioassay results indicate the potential 
for VECTRON T500 to last well beyond 6 months in village-type housing. Ongoing studies in Benin will assess 
the residual efficacy of VECTRON T500 for IRS in human occupied experimental huts for 12 months.
Compared to cement plastered walls, mud walls are often considered a more challenging substrate for IRS usu-
ally resulting in shorter residual vector mosquito  control30,34. By contrast, our study demonstrated longer residual 
efficacy of VECTRON T500 in laboratory cone bioassays with the susceptible Kisumu strain on mud block sub-
strates (> 80% mortality for 18 months) compared to cement block substrates (> 80% mortality for 6 months). 
This corroborates our previous findings in similar studies with another IRS  insecticide27. The improved residual 
efficacy with the mud block substrates could be attributed to the addition of a small amount of cement to the mud 
paste during the preparation of the block substrates, in line with local practices in some areas in Benin, making 
the substrates more stable and less porous. Nevertheless, it is worth noting that contrary to the laboratory study, 
mortality of wild free flying vector mosquitoes and residual efficacy in wall cone bioassays in the VECTRON 
T500-treated experimental huts, did not differ between both substrate-types.
As new modes of action are introduced for vector control, it is essential to investigate the potential for cross-
resistance to these insecticides and existing insecticide resistance mechanisms in vector populations as this could 
severely limit the usefulness of the new chemistry. The small resistance ratio observed in CDC bottle bioassays 
(2.1) and high cone bioassay mortality rates (> 80% for 6–14 months) achieved with the pyrethroid-resistant An 
gambiae sl strain from Covè—a strain which has shown > 200 fold resistance to pyrethroids mediated by high 
kdr frequencies and overexpressed detoxifying P450  enzymes23—would indicate the absence of cross-resistance 
to broflanilide and pyrethroids. This demonstrates the potential of broflanilide WP to effectively control malaria 
vector populations that have developed intense resistance to pyrethroids. Although mutations in the GABA recep-
tor conferring resistance to some non-competitive antagonist agrochemicals such as cyclodienes and fipronil 
have been reported in malaria vectors across  Africa35,36, the site of action of broflanilide within the GABA 
receptor has been demonstrated to be distinct from that of non-competitive  antagonist20. This suggests a low 
probability of cross-resistance to broflanilide in malaria vectors. Indeed, recent studies in which broflanilide was 
tested against a strain of An. gambiae Kisumu containing mutations in the GABA receptor conferring resistance 
to dieldrin (RDL), found a very low resistance ratio (1.73) compared to the susceptible Kisumu strain which 
would indicate the absence of cross-resistance to broflanilide and  dieldrin37. Mutations in the GABA receptor 
which confer resistance to meta-diamides have however been detected in  Drosophila20. Studies to investigate 
Table 4.  Results for chemical analysis of filter papers from experimental huts treated with broflanilide WP and 
pirimiphos-methyl CS.
Treatment Negative control Broflanilide WP Pirimiphos-methyl CS
Substrate Cement Cement Mud Cement
Target dose (mg/m2) – 100 150 100 150 1000
Filter paper dosed (mg/m2) 0 107 112 137 112 688
95% CI – [99–115] [103–122] [129–145] [95–130] [95–130]
Deviation from target dose –  + 7% − 25%  + 37% − 19% − 31%
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the possible presence of this mutation and other mechanisms that could confer resistance to broflanilide in wild 
populations of malaria vectors will be advisable.
Despite its strong anthropophilic behaviour, a considerable number of An gambiae (81% An. coluzzii and 19% 
An. gambiae ss), were attracted to the cow hosts during the experimental hut trial, although the numbers were 
substantially lower than what would be expected in hut trials with human volunteer sleepers at the Covè experi-
mental hut  station14,15. The animal bait also attracted a more zoophilic Anopheline species into the experimental 
huts—An. ziemanni. Although this species has been much less studied compared to the An. gambiae complex, 
An. ziemanni has been previously implicated in malaria transmission in the North West region of  Cameroon38 
and suspected to transmit malaria in Western  Kenya39. Such secondary vectors have been recognized for their 
importance in malaria transmission, as they may help to augment or extend the malaria transmission period. In 
our study, broflanilide killed 74–88% of wild An. ziemanni entering the experimental huts over the 6-month trial 
thus demonstrating the potential of the insecticide to control this Anopheline species which could be sustaining 
malaria transmission as a secondary vector in some parts of Africa.
Among the strategies proposed by the GPIRM for mitigating the impact of insecticide resistance in malaria 
vectors, the rotation of IRS formulations containing insecticides with different modes of action is currently 
considered the most promising tactic for insecticide resistance  management12. The uptake of this strategy has 
been seriously limited by the very restricted number of safe and long-lasting IRS insecticides available to malaria 
control  programmes40. Two new IRS formulations containing clothianidin (a neonicotinoid) have recently been 
added to the WHO’s list of pre-qualified vector control products, and are already being deployed for IRS in many 
endemic  countries13. It is, however, crucial that vector control programmes do not become overly dependent on 
any one mode of action for IRS as this may lead to resistance evolving more rapidly. For the rotational strategy to 
work optimally, several modes of action need to be available at the same time to allow sub-national rotations and 
restrict selection of resistance to any single class of insecticide. Based on its novel mode of action and efficacy for 
IRS against pyrethroid-resistant malaria vectors as demonstrated in the present study, VECTRON T500 shows 
potential to effectively complement other IRS insecticide formulations in an IRS rotation plan that can manage 
insecticide resistance and extend the effective lives of these promising new insecticides.
Conclusion
In this study, we demonstrate the efficacy of a wettable powder formulation of broflanilide (VECTRON T500), a 
newly discovered insecticide with a novel mode of action, for IRS against wild malaria vectors. VECTRON T500 
showed high activity against both pyrethroid-susceptible and resistant strains of An. gambiae sl which lasted 
6 months or more on local cement and mud substrates in both laboratory bioassays and experimental hut stud-
ies. Indoor residual spraying with broflanilide WP shows potential to provide improved and prolonged control 
of pyrethroid-resistant malaria vector populations.
Materials and methods
WHO phase I laboratory bioassays. CDC bottle bioassays to investigate resistance to broflanilide. The 
CDC bottle bioassays were performed with unfed 2–5 days old insecticide-susceptible An. gambiae ss Kisumu 
and pyrethroid-resistant An. gambiae sl adult female mosquitoes from Covè, Benin. Eight doses were selected 
between 5 µg/bottle and 200 µg/bottle as follows: 5 µg, 10 µg, 16.5 µg, 27.1 µg, 44.7 µg, 73.7 µg, 121.4 µg and 
200 µg based on results from preliminary studies. Stock solutions were prepared by serial dilutions of the techni-
cal grade insecticide in acetone. 1 ml of each stock solution was used to coat each 250 ml Wheaton bottle and 
6 bottles were prepared per dose as described in the CDC bottle bioassay  guideline41. The CDC bottle bioassay 
protocol was modified; approximately 100–150 female mosquitoes per insecticide dose were exposed for 1 h in 
cohorts of 25 mosquitoes per bottle. Mosquitoes were held at 27 °C ± 2 °C and 80 ± 10% RH and mortality re-
corded after 72 h based on preliminary evidence of a slower mode of action of broflanilide. Mosquitoes were also 
exposed to untreated control and alpha-cypermethrin 12.5 µg treated bottles for comparison. Estimates of the 
dose required to kill 50% (LD50) and 95% (LD95) of each strain and the resistance ratio of the wild Covè strain 
relative to the susceptible Kisumu strain were generated by log dosage-probit analysis (PoloPlus version 1.0).
Preparation and treatment of block substrates. Cement and mud block substrates used in cone bioassays were 
prepared and treated using similar methods described in previous studies by our  group27. Blocks were moulded 
in Petri dishes (9 cm diameter and 1 cm thick) and dried at 30 °C ± 2 °C and 80 ± 10% RH for 30 days before 
insecticide application. Cement blocks were made by mixing cement with sand at a 1:1 ratio while mud blocks 
were made from local mud paste to which 10% cement was added to improve its durability and reduce cracking, 
in line with local practices. These substrates were treated using a Potter tower sprayer (Burkard Manufacturing 
Co Ltd) to achieve a homogeneous and accurate deposit of the target concentration of active ingredient (a.i) per 
unit area as described in WHO testing  guidelines22. Blocks were weighed before and after treatments to ensure 
the target amount of insecticide was delivered. All treated blocks were stored, unsealed at 30  °C ± 2  °C and 
80% ± 10% RH in between bioassays. Four replicate blocks of each substrate-type were prepared for each dose 
of insecticide tested.
Dose–response cone bioassays. The dose–response cone bioassays were performed on mud and cement blocks 
treated with broflanilide WP at application rates of 5 mg/m2, 12.5 mg/m2, 25 mg/m2, 50 mg/m2 and 100 mg/m2, 
1-week post block treatment using the insecticide-susceptible An. gambiae ss Kisumu strain. For each dose and 
substrate-type, forty (40) unfed 2–5 days old mosquitoes were exposed for 30 min in cohorts of 10 mosquitoes 
per cone and per block. Mosquitoes were held at 27 °C ± 2 °C and 80% ± 10% RH post-exposure and knockdown 
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was recorded after 1 h. To investigate delayed mosquito mortality with broflanilide WP, mortality was recorded 
every 24 h for up to 120 h.
Residual efficacy of broflanilide WP (VECTRON T500) in laboratory cone bioassays. For each insecticide dose 
and substrate-type used for assessment of residual efficacy, forty (40) unfed 2–5 days old female mosquitoes were 
exposed in cone bioassays for 30 min in cohorts of 10 mosquitoes per block as described in WHO  guidelines22. 
Mosquitoes were held under the same conditions as described earlier and mortality recorded every 24 h for up to 
72 h. Bioassays were performed monthly for up to 6 months post-treatment and subsequently every two months 
for up to 18 months post-treatment.
WHO phase II experimental hut trial. Experimental hut site. The experimental hut site is located in 
an irrigated valley producing rice almost year-round and providing suitable breeding habitats for mosquitoes. 
The rainy season extends from March to October and the dry season from November to February. The vector 
population is susceptible to carbamates and organophosphates but over 200-fold resistant to  pyrethroids23,42. It 
consists of both An. coluzzii and An. gambiae sensu stricto (s.s.) with the latter occurring at lower frequencies 
(~ 23%) and mostly in the dry  season23. The experimental huts used were of the West African design and are 
made from cement bricks with a corrugated iron roof. Each hut was built on a cement plinth surrounded by a 
water-filled moat to prevent the entry of scavenging ants and had a wooden framed veranda trap to capture exit-
ing  mosquitoes22. Mosquito entry occurred via four 1-cm window slits situated on three sides of the hut.
Application of IRS treatments. Six experimental huts were used for the study. Preliminary mosquito collections 
at the hut site revealed that the chosen huts were equally attractive to mosquitoes. The following 6 treatments 
were tested in the huts:
1. Untreated hut (negative control)—cement-walled hut.
2. Broflanilide WP (VECTRON T500) applied at 100 mg/m2—cement-walled hut.
3. Broflanilide WP (VECTRON T500) applied at 100 mg/m2—mud-walled hut.
4. Broflanilide WP (VECTRON T500) applied at 150 mg/m2—cement-walled hut.
5. Broflanilide WP (VECTRON T500) applied at 150 mg/m2—mud-walled hut.
6. Pirimiphos-methyl CS (Actellic 300CS) applied at 1000 mg/m2—cement-walled hut.
The IRS treatments were randomly allocated to experimental huts and were applied using a Hudson Xpert 
compression sprayer equipped with a 8002 flat-fan nozzle and calibrated. To improve spray accuracy, spray swaths 
were marked before spraying and sprayed from the top to the bottom using a predetermined lance speed. After 
spraying each hut, the volume remaining in the spray tank was measured to assess the overall volume sprayed. 
All spray volumes were within 30% of the target.
Hut trial procedure. Six (6) cows were brought to sleep in the huts from 21:00 to 06:00 each trial night and 
were rotated between huts on successive nights to adjust for variation in individual attractiveness to mosquitoes. 
The cows were maintained according to institutional and national guidelines for the protection of experimental 
animals. The trial ran for 6 months from September 2018 to March 2019 and followed WHO  guidelines22. Data 
collection was performed for 6 nights each week. On the 7th day of each week, the huts were cleaned and aired 
in preparation for the next cycle. Each morning, mosquitoes were collected from the room and veranda and 
brought to the laboratory where they were identified using standard identification keys and scored as fed or 
unfed and dead or alive. Live mosquitoes were provided with 10% glucose solution and mortality scored every 
24 h for up to 72 h.
Outcome measures in experimental huts. The efficacy of each experimental hut treatment was expressed in 
terms of the following outcome measures:
• Exiting rates—the proportion of mosquitoes collected in the veranda.
• Blood-feeding rates—the proportion of blood-fed mosquitoes.
• Mortality—the proportion of mosquitoes found dead after a 72-h holding time.
Monthly residual cone bioassays on treated experimental hut walls. Five cones were fixed to each treated surface 
of each hut (1 per wall + 1 on the ceiling). Approximately fifty (50) unfed 2–5 days old mosquitoes of each strain 
(insecticide-susceptible An. gambiae ss Kisumu and pyrethroid-resistant An. gambiae sl Covè) were exposed for 
30 min to each hut treatment in batches of 10 mosquitoes per cone. After exposure, mosquitoes were transferred 
into netted plastic cups and supplied with 10% sugar solution. Mortality was recorded every 24 h up to 72 h.
Data management and statistical analysis. Cone bioassay data were pooled for each substrate and 
dose and mean mortalities obtained using Microsoft Excel. CDC bottle bioassay data were analysed using log 
dosage-probit mortality analysis (Poloplus version 1.0) to determine the lethal concentration (LC) required to 
kill 50% (LC50) and 95% (LC95) of exposed mosquitoes. The resistance ratio of the pyrethroid-resistant An 
gambiae s.l. Covè strain was obtained by dividing its LC50 by that of the susceptible Kisumu strain. Proportional 
outcomes (blood-feeding, exophily and mortality) for each experimental hut treatment were analysed using 
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blocked logistic regression in Stata version 15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC) with adjustments for the attractiveness of the individual cow hosts.
Ethical considerations. Institutional ethical approval for the study was obtained from the Ethics Review 
Committee of the Ministry of Health Benin (Ethical decision n°39). The cows used in experimental huts to 
attract mosquitoes were maintained following institutional standard operating procedures (SOPs) designed to 
improve care and protect animals used for experimentation. During the day, the cows were allowed to graze 
freely in an open field not too far from the experimental hut site. A veterinarian was available throughout the 
study to examine them daily and any cows found unwell were replaced and treated appropriately. All studies 
were performed according to relevant national and international guidelines.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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